● Recruiting

Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia

Condition: Acute Myeloid Leukemia, in Relapse · Acute Myeloid Leukemia Refractory · Sponsor: University Hospital, Antwerp

PhasePhase 1

Planned participants10

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

Non-commercial, open-label interventional phase Ib study to assess the effectivity of the combination of venetoclax and 6-mercaptopurine in patients with relapsed or refractory AML.

This description comes directly from the study's public registry record.

Talk to the study team

Sébastien Anguille, Prof. Dr. · 0032 3 821 3356 · studies.hematologie@uza.be

Always discuss trial participation with your own doctor first.

Locations (2)

University Hospital Antwerp	Edegem, Antwerp, Belgium	Recruiting
AZ Delta	Roeselare, West Vlaanderen, Belgium	Not Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05506332